Journal
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
Volume 322, Issue 3, Pages 267-269Publisher
AMER MEDICAL ASSOC
DOI: 10.1001/jama.2019.7521
Keywords
-
Categories
Funding
- National Institute on Aging [T32-AG000186]
- Arnold Ventures, Engelberg Foundation
- Harvard-MIT Center for Regulatory Science
Ask authors/readers for more resources
This study characterizes price increases exceeding inflation between 2012 and 2017 for protected-class drugs (antineoplastics, antiretrovirals, antidepressants, antipsychotics, anticonvulsants, and immunosuppressants for transplant patients) that would lead to their exclusion from Medicare Part D coverage based on excessive cost under a 2018 CMS rule intended to facilitate more effective price negotiations.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available